Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN72792659
ISRCTN72792659
Completed
Not Applicable

Prospective randomised phase II clinical trial of epirubicin, cisplatin, continuous infusional 5-fluorouracil (ECF) versus epirubicin, cisplatin and capecitabin (ECX) in patients with advanced gastric cancer

Ministry of Higher Education, Science and Technology (Slovenia)0 sites80 target enrollmentNovember 13, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Ministry of Higher Education, Science and Technology (Slovenia)
Enrollment
80
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ministry of Higher Education, Science and Technology (Slovenia)

Eligibility Criteria

Inclusion Criteria

  • •1\. Both males and females, age 18 years or older
  • •2\. Histologically confirmed advanced gastric cancer
  • •3\. Performance status of 0\-2
  • •4\. Adequate bone marrow function
  • •5\. Adequate renal, hepatic function
  • •7\. Normal cardiac function
  • •8\. Estimated life expectancy more than 3 months

Exclusion Criteria

  • •1\. Performance status more than 2
  • •2\. Patients not recovered from operation
  • •3\. Patients with unresolved intestinal obstruction
  • •4\. Malabsorption syndrome
  • •5\. Pregnancy
  • •6\. Breastfeeding or childbearing potential without using adequate contraception
  • •7\. Cardiovascular diseases (New York Heart Association \[NYHA] III\-IV)
  • •8\. Impaired renal function
  • •9\. Liver diseases
  • •10\. Active hepatitis (hepatitis B, hepatitis C)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemia
ACTRN12620000850976epean Blue Mountains Local Health District134
Completed
Phase 2
Phase II randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancerMetastatic breast cancer
JPRN-UMIN000027382Kyushu Breast Cancer Study Group (KBC-SG)90
Active, not recruiting
Phase 1
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
Completed
Not Applicable
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.
JPRN-UMIN000019817Department of Surgery, Kansai Medical University80
Active, not recruiting
Phase 2
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)
2024-514527-42-00Karolinska Institutet, Karolinska Institutet62